AICDA

Across TCGA pan-cancer cohorts, AICDA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AICDA data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher AICDA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AICDA expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUSC, READ, and UCEC are the cancer types where AICDA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.621	.012	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LIHC	DFS	Median	II,III,IV	0.080	0.414	.027	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.671	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AICDA–LUSC (DFS)

Open the LUSC breakdown →